.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AX03_Temozolomide.Temozolomide .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AX03_Temozolomide.Temozolomide| name: | Temozolomide |
| ATC code: | L01AX03 | route: | oral |
| n-compartments | 1 |
Temozolomide is an oral alkylating agent, primarily used in the treatment of certain brain tumors such as glioblastoma multiforme and anaplastic astrocytoma. It is approved for use in many countries and is considered a standard of care for high-grade gliomas.
Pharmacokinetic parameters reported for adult cancer patients (glioblastoma), mixed sexes, typical age range 18-70 years, normal renal and hepatic function.
Singh, R, et al., & Beumer, JH (2019). Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias. Cancer chemotherapy and pharmacology 83(2) 319–328. DOI:10.1007/s00280-018-3731-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30456480
Büsker, S, et al., & Peyrl, A (2022). Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors. Cancer chemotherapy and pharmacology 89(5) 617–627. DOI:10.1007/s00280-022-04424-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35355137
Panetta, JC, et al., & Stewart, CF (2003). Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. Cancer chemotherapy and pharmacology 52(6) 435–441. DOI:10.1007/s00280-003-0670-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/13680158